citalopram +pharma 20mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 10628 citalopram-hydrobromid - potahovaná tableta - 20mg - citalopram
citalopram teva 10mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 10628 citalopram-hydrobromid - potahovaná tableta - 10mg - citalopram
citalopram teva 20mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 10628 citalopram-hydrobromid - potahovaná tableta - 20mg - citalopram
citalopram teva 40mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 10628 citalopram-hydrobromid - potahovaná tableta - 40mg - citalopram
escitalopram +pharma 10mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 16590 escitalopram-oxalÁt - potahovaná tableta - 10mg - escitalopram
escitalopram teva 10mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 16590 escitalopram-oxalÁt - potahovaná tableta - 10mg - escitalopram
itakem 10mg potahovaná tableta
actavis group ptc ehf., hafnarfjördur array - 16590 escitalopram-oxalÁt - potahovaná tableta - 10mg - escitalopram
itakem 20mg potahovaná tableta
actavis group ptc ehf., hafnarfjördur array - 16590 escitalopram-oxalÁt - potahovaná tableta - 20mg - escitalopram
itakem 5mg potahovaná tableta
actavis group ptc ehf., hafnarfjördur array - 16590 escitalopram-oxalÁt - potahovaná tableta - 5mg - escitalopram
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastická činidla - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.